Breaking New Ground in Cervical Metastatic Carcinoma of Unknown Primary: Neoadjuvant Immunochemotherapy's Pathologic Regression and Survival Advantage.

BACKGROUND: Cervical metastatic carcinoma of unknown primary (CMCUP) poses significant therapeutic challenges because of its aggressive biology and the absence of standardized treatment protocols. While neoadjuvant immunochemotherapy (NICT) has demon…

Preview only. Read the full abstract at the source